You will now be redirected to the GD3 website
Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3Biochemistry & Bioanalytical
In Vivo DMPK
GD3 offers comprehensive preclinical pharmacokinetic and drug metabolism studies for rodents and rabbits. Our experienced scientists specialize in both systemic and ocular research, working with a diverse range of both small and large molecules including amino acids, nucleic acids, peptides, antibodies, and adeno-associated viruses.
For ocular dosing, we provide expert services from our trained research associates or a board-certified veterinary ophthalmologist. To complement pharmacokinetic studies, we offer a variety of pharmacodynamic endpoints, including OCT, FA, and ERG.
- Formulation screening
- Lead optimization
- Bioequivalence studies
- Bioavailability studies
- Biodistribution studies
- Pharmacokinetic studies
- Tolerability studies
- Maximum tolerated dose studies
- Single and multiple dose
- Systemic and ocular dosing
- Method development for novel dosing routes
- Pharmacodynamics endpoints
Routes of Administration:
-
Systemic:
- Oral gavage
- Subcutaneous
- Intravenous/infusion
- Intraperitoneal
- Intramuscular
- Dermal
- Intranasal inhalation/instillation
-
Ocular
- Intravitreal
- Intracameral
- Subretinal
- Suprachoroidal
- Subconjunctival
- Topical
Full necropsy capabilities, including extensive ocular dissection expertise:
-
Collection Anterior
- Aqueous humor, cornea, conjunctiva (palpebral and/or bulbar)
- Meibomian glands
- Trabecular meshwork, iris-ciliary body, lens
-
Posterior
- Vitreous humor, optic nerve
- Sclera, choroid (central and/or peripheral)
- Retina (central and/or peripheral)
Learn more about Bioanalysis